Analysts Set Dyne Therapeutics, Inc. (NASDAQ:DYN) Target Price at $32.17

Dyne Therapeutics, Inc. (NASDAQ:DYN) has received an average rating of “Moderate Buy” from the sixteen analysts that are presently covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell rating, one has given a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $32.1667.

Several brokerages recently issued reports on DYN. Raymond James Financial reiterated a “strong-buy” rating and issued a $37.00 target price on shares of Dyne Therapeutics in a research note on Tuesday, September 8th. Royal Bank Of Canada decreased their target price on Dyne Therapeutics from $35.00 to $30.00 and set an “outperform” rating on the stock in a report on Wednesday, September 9th. TD Cowen started coverage on Dyne Therapeutics in a research note on Friday, June 26th. They issued a “buy” rating on the stock. Robert W. Baird reduced their target price on shares of Dyne Therapeutics from $30.00 to $26.00 and set an “outperform” rating for the company in a report on Wednesday, September 9th. Finally, Morgan Stanley cut their price objective on shares of Dyne Therapeutics from $45.00 to $36.00 and set an “overweight” rating for the company in a research report on Wednesday, September 9th.

Insider Buying and Selling at Dyne Therapeutics

In other news, Director Jason Rhodes sold 2,160,516 shares of the firm’s stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $25.00, for a total transaction of $54,012,900.00. Following the transaction, the director directly owned 428,946 shares of the company’s stock, valued at approximately $10,723,650. This trade represents a 83.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Cox sold 5,658 shares of the stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $18.88, for a total transaction of $106,823.04. Following the sale, the chief executive officer owned 357,507 shares in the company, valued at $6,749,732.16. The trade was a 1.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 4,150,974 shares of company stock worth $99,697,629. Insiders own 9.46% of the company’s stock.

Institutional Investors Weigh In On Dyne Therapeutics

Several hedge funds have recently modified their holdings of the company. Handelsbanken Fonder AB acquired a new position in shares of Dyne Therapeutics in the second quarter valued at approximately $1,182,000. Fisher Asset Management LLC acquired a new position in Dyne Therapeutics in the 4th quarter valued at approximately $4,891,000. Royal Bank of Canada raised its stake in shares of Dyne Therapeutics by 267.6% during the first quarter. Royal Bank of Canada now owns 68,188 shares of the company’s stock valued at $1,236,000 after acquiring an additional 49,641 shares during the last quarter. Flputnam Investment Management Co. acquired a new position in shares of Dyne Therapeutics during the second quarter worth $1,177,000. Finally, Cibc World Market Inc. bought a new stake in shares of Dyne Therapeutics in the fourth quarter worth $1,345,000. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Trading Down 5.3%

Shares of NASDAQ:DYN opened at $17.11 on Wednesday. The company’s 50-day moving average price is $24.00 and its two-hundred day moving average price is $20.60. The company has a debt-to-equity ratio of 0.28, a current ratio of 12.02 and a quick ratio of 12.02. Dyne Therapeutics has a one year low of $11.92 and a one year high of $27.31. The stock has a market capitalization of $3.20 billion, a PE ratio of -5.14 and a beta of 1.08.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.33). On average, equities analysts forecast that Dyne Therapeutics will post -3.59 EPS for the current fiscal year.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc is a biotechnology company focused on developing treatments for genetically driven muscle diseases. The company uses its FORCE platform, which is designed to deliver oligonucleotide therapeutics to skeletal muscle and other tissues by combining muscle-targeting antibodies with genetic medicines.

Dyne’s research and development programs are aimed at conditions in which the underlying genetic mutations impair muscle function. Its pipeline has included DYNE-101 for myotonic dystrophy type 1 and DYNE-251 for Duchenne muscular dystrophy in patients with mutations amenable to exon 51 skipping.